NTRK1 and pancreatic neoplasm: Moreover, BMS-754807 has been known to have off-target effects in inhibiting the activation of tropomyosin-receptor-kinase A and B (TrkA and TrkB) and aurora kinases in pancreatic cancer [65], which influenced their therapeutic efficacy.